RightFit
RecruitingPhase not listed

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tracks how safe and helpful GLP-1RA or SGLTi medicines are when used along with insulin for 1 year. It is for adults with type 1 diabetes whose health care provider has prescribed one of these added medicines as part of their usual care.

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are 18 or older.
  • You have been diagnosed with type 1 diabetes.
  • Your provider prescribed a GLP-1RA or SGLTi medicine for any reason as part of your usual care. You have used it for no more than 1 week. SGLTi medicines include SGLT-1 and SGLT-2 inhibitors.
  • You use a continuous glucose monitor (CGM), a device that tracks blood sugar. You have CGM data from the month before joining and expect to have data throughout the study.
  • You are willing and able to give informed consent, which means you understand the study and agree to join.

Who can't join

  • There are no other reasons listed that would keep you from joining, as long as you meet all the requirements above.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Adults ≥18 years of age * Clinical diagnosis of T1D * GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week * Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study * Willing and able to provide informed consent Exclusion Criteria: * No exclusion criteria other than those not meeting inclusion criteria above

Study sites (17)

CA

FL

GA

IL

KY

MA

ME

MI

MN

NE

NY

OH

VA